Inventor · disambiguated record
Joseph Naemura
Also filed as: NAEMURA JOSEPH R · NAEMURA JOSEPH ROY · NAEMURA Joseph
9 granted patents·6 pending applications·297 citations·filing 1998–2020
91Inventor score
Top patents by PatentIndex Score
15 records- 0197US7094874B2Soluble CTLA4 mutant moleculesBRISTOL MYERS SQUIBB CO·Filed 2001·Granted Aug 22, 2006·86 cites·42 claims
- 0295US7304033B2Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant moleculesBRISTOL MYERS SQUIBB CO·Filed 2002·Granted Dec 4, 2007·90 cites·32 claims
- 0393US7700556B2Methods of treatment using CTLA4 mutant moleculesBRISTOL MYERS SQUIBB CO·Filed 2007·Granted Apr 20, 2010·14 cites·8 claims
- 0492US7455835B2Methods for treating immune system diseases using a soluble CTLA4 moleculeBRISTOL MYERS SQUIBB CO·Filed 2001·Granted Nov 25, 2008·57 cites·31 claims
- 0590US7829534B2Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant moleculesBRISTOL MYERS SQUIBB CO·Filed 2007·Granted Nov 9, 2010·16 cites·14 claims
- 0690US7439230B2Methods of treatment using CTLA4 mutant moleculesBRISTOL MYERS SQUIBB CO·Filed 2004·Granted Oct 21, 2008·22 cites·16 claims
- 0789US9758565B2Methods of treatment using CTLA4 mutant moleculesBRISTOL MYERS SQUIBB CO·Filed 2014·Granted Sep 12, 2017·6 cites·14 claims
- 0884US8785398B2Methods of treatment using CTLA4 mutant moleculesPEACH ROBERT JAMES·Filed 2011·Granted Jul 22, 2014·6 cites·11 claims
- 0977US2021115107A1Methods of treatment using ctla4 moleculesBRISTOL MYERS SQUIBB CO·Filed 2020·Application pending·0 cites
- 1070US2019185538A1Methods of treatment using ctla4 moleculesBRISTOL MYERS SQUIBB CO·Filed 2018·Application pending·0 cites
- 1168US10370428B2Methods of treatment using CTLA4 mutant moleculesBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Aug 6, 2019·0 cites·10 claims
- 1257US2004014171A1Soluble CTLA4 mutant molecules and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2003·Application pending·0 cites
- 1357US2010183612A1Methods of treatment using ctla4 mutant moleculesBRISTOL MYERS SQUIBB CO·Filed 2010·Application pending·0 cites
- 1451US2003219863A1Soluble CTLA4 mutant molecules and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2003·Application pending·0 cites
- 1531US2003035816A1Soluble ctla4 mutant molecules and uses thereofFiled 1998·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →